These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37787054)

  • 1. Public health impact of 2-, 4-, and 9-valent HPV vaccination in females on cervical and noncervical diseases in men and women under different coverage scenarios in China: A simulation study.
    Diakite I; Kyle J; Situ S; Bai P; Zhang X; Wang W; Daniels V
    Hum Vaccin Immunother; 2023 Aug; 19(2):2258569. PubMed ID: 37787054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France.
    Majed L; Bresse X; El Mouaddin N; Schmidt A; Daniels VJ; Pavelyev A; Levy-Bachelot L; Elbasha E
    Vaccine; 2021 Jan; 39(2):438-446. PubMed ID: 33261895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
    Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
    BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study.
    Li Y; Lin YF; Wu X; Zhou X; Tian T; Guo Z; Fu L; Yang L; Lu Z; Fan S; Lu Y; Ke W; Zou H
    Front Immunol; 2023; 14():1197191. PubMed ID: 37426648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
    BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2013 Aug; 31(37):3899-905. PubMed ID: 23820080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M; Bénard É; Pérez N; Brisson M;
    Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
    Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
    Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
    Dasbach EJ; Insinga RP; Elbasha EH
    BJOG; 2008 Jul; 115(8):947-56. PubMed ID: 18503574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
    J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.
    Prem K; Choi YH; Bénard É; Burger EA; Hadley L; Laprise JF; Regan MC; Drolet M; Sy S; Abbas K; Portnoy A; Kim JJ; Brisson M; Jit M
    BMC Med; 2023 Aug; 21(1):313. PubMed ID: 37635227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health impact and cost effectiveness of implementing gender-neutral HPV vaccination in Japan.
    Palmer C; Tobe K; Negishi Y; You X; Chen YT; Abe M
    J Med Econ; 2023; 26(1):1546-1554. PubMed ID: 37962015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of nonavalent HPV vaccination in the Netherlands.
    Palmer C; Dolk C; Sabale U; Wang W; Saxena K
    Expert Rev Vaccines; 2024; 23(1):312-323. PubMed ID: 38417025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
    Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
    Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.